Neuropeptide Y Receptors Switch Their Role in Pain Depending on Whether You're Injured or Not

What the researchers found

The review resolves conflicting findings about the NPY Y2 receptor by proposing a G protein switch model. In the normal state, blocking Y2 receptors (with BIIE0246) causes pain and hypersensitivity. After nerve injury or inflammation, the same Y2 blocker paradoxically reduces mechanical and thermal hypersensitivity and improves the emotional dimension of pain. In chronic pain models of latent sensitization, Y2 blockade causes a profound return of pain-like behaviors. This suggests Y2 signaling switches from antinociception (normal) to anti-hyperalgesia (injured) and back to antinociception (remission).

Why it matters

The opioid crisis has created urgent demand for non-opioid pain therapies. NPY Y2 receptors represent a largely untapped target in the spinal pain pathway. By clarifying when Y2 antagonists help versus hurt, this review provides a roadmap for developing targeted Y2-based therapies for chronic pain patients — specifically those who do not develop latent sensitization.

How the study worked

This is a narrative review synthesizing evidence from neurophysiological slice recordings, behavioral pharmacology studies in animal models, and chronic pain models of latent sensitization. The authors integrated findings across multiple experimental paradigms to propose a unified mechanistic model.

What this study cannot tell us

This is a review paper synthesizing primarily animal studies — the proposed G protein switch model has not been directly confirmed in humans. The behavioral pharmacology data relies heavily on a single Y2 antagonist (BIIE0246), and off-target effects cannot be entirely ruled out. The concept of latent sensitization and its relevance to human chronic pain conditions is still being established. Clinical translation remains speculative.

How to read the evidence

This is a narrative review that synthesizes existing preclinical research to propose a new mechanistic model. While it integrates evidence from multiple studies, the proposed model is theoretical and based on animal data. It represents an expert synthesis rather than new experimental evidence.

When this study was published

Published in 2024, this review represents the current state of understanding of NPY Y2 receptor pharmacology in pain and resolves contradictions that have persisted in the field for years.

The bigger picture

Neuropeptide Y is one of the most abundant peptides in the central nervous system, yet its therapeutic potential for pain has been complicated by contradictory findings. This review's proposed switch model brings clarity to a confusing field and could catalyze drug development efforts. As the pharmaceutical industry searches for non-opioid analgesics, peptide receptor targets like Y2 are increasingly attractive because they can modulate pain signaling with potentially fewer side effects than broad-acting drugs.

Questions still open

• Can the proposed G protein switch in Y2 signaling be directly demonstrated at the molecular level in injured tissue?
• Which chronic pain patient populations would benefit from Y2 antagonists versus which might be harmed?
• Could selective Y2 receptor modulators be developed that avoid the paradoxical pronociceptive effects seen in latent sensitization models?

Common questions

Read the original research

Neuropeptide Y Y2 receptors in acute and chronic pain and itch.

Neuropeptides, 108, 102478

Citation

Basu, Paramita; Taylor, Bradley K. (2024). Neuropeptide Y Y2 receptors in acute and chronic pain and itch.. Neuropeptides, 108, 102478. https://doi.org/10.1016/j.npep.2024.102478